文献速递免疫规划慢病防控与筛查

mRNA新冠疫苗在心脏淀粉样变性患者中安全且具有临床有效性

mRNA vaccines for COVID-19 are safe and clinically effective in patients with cardiac amyloidosis.
PubMed 文献 · Vaccine · 2023-12-28

该研究评估了mRNA新冠疫苗在心脏淀粉样变性患者中的安全性与有效性。结果显示无严重副作用,无疫苗诱导心肌炎证据,5例突破感染均为轻症,结论为mRNA疫苗对心脏淀粉样变性患者安全且有效保护。

要点

  • 心脏淀粉样变性患者接种mRNA新冠疫苗后未报告严重副作用。
  • 无临床或实验室证据提示疫苗诱导心肌炎。
  • 5例突破感染均为轻症,无疫苗接种后心力衰竭加重症状。

核心结论

  • 在心脏淀粉样变性患者中,mRNA新冠疫苗在严重心脏不良事件方面是安全的,并显示出对临床相关SARS-CoV2感染的有效保护。

主要发现

  • 46例患者为wtATTR淀粉样变性,10例为hATTR淀粉样变性,6例为AL淀粉样变性。
  • 59例患者接种三剂疫苗,3例接种两剂,3例未接种;接种的疫苗剂量中171剂为mRNA疫苗,8剂为病毒载体疫苗。
  • 13例报告注射部位压迫感和疼痛,4例发热最长两天,8例一般状况下降最长五天,1例每次接种后不适14天并自行缓解。
  • 5例报告COVID-19突破感染,均为轻症;无患者出现与疫苗接种时间相关的心力衰竭加重症状;103剂在官方接种中心接种,59剂在全科医生处接种。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Amyloidosis is a rare disease in which malformed proteins are deposited in tissues occurring mostly commonly in older age. These deposits can lead to severe organ dysfunction e.g. in the myocardium with great impact on prognosis. The Covid-19 pandemic has caused excess mortality worldwide since 2020. Risk factors for a severe course include pre-existing cardiac diseases like heart failure and advanced age. Therefore, vaccination against Sars-CoV2 viruses is highly recommended for patients with cardiac amyloidosis. However, since there are no specific data on mRNA vaccines in patients with cardiac amyloidosis, some patients have concerns about cardiac adverse events following immunization (AEFI), such as myocarditis. PURPOSE: The purpose of the study is to assess the safety and efficacy of mRNA vaccines in patients with cardiac amyloidosis. METHODS: Patients of the Amyloidosis Center Charité Berlin (ACCB) were assessed about the vaccination, its tolerability and clinical effectiveness. To date, we included 62 patients (54 men) with a median age of 82,5 years (range 37 to 92). 46 patients had wtATTR amyloidosis, ten patients had hATTR amyloidosis, and six patients had AL amyloidosis. The mean systolic left ventricular function was 51% (range 30 to 62) with a mean global strain of -11,5% (range -18,5 to -3,1). The mean NT-pro-BNP was 1145 ng/l (range 24 to 48297). RESULTS: 59 patients were triple vaccinated and three patients so far are double vaccinated. Three of the patients were unvaccinated. 171 of the vaccine doses administered were mRNA vaccines and eight doses were a viral vector-vaccine. None of the patients reported severe side effects. Thirteen patients reported feeling of pressure and pain at the injection site after vaccination and four patients had fever of maximum two days, eight patients reported lower general condition of maximum five days. One patient reported malaise for 14 days after each vaccination, which resolved spontaneously. There was no clinical or laboratory evidence of suspected vaccine-induced myocarditis. Five patients reported of a COVID-19 breakthrough infection, all of which with a mild course of disease. None of the patients had symptoms of worsening heart failure in temporal relation to the vaccination. Most of the vaccinations (103) were performed at an official vaccination center, 59 were performed at a general practitioner. CONCLUSION: In patients with cardiac amyloidosis, mRNA vaccines for COVID-19 are safe with respect to severe cardiac adverse events and show effective protection against clinically relevant SARS-CoV2 infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Barzen G, Rieber F, Stangl K, et al. mRNA vaccines for COVID-19 are safe and clinically effective in patients with cardiac amyloidosis. Vaccine. 2023. PMID: 38158299. doi:10.1016/j.vaccine.2023.12.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。